^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gallbladder Cancer

    Related cancers:
    4d
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=168, Active, not recruiting, Compass Therapeutics | Completed --> Active, not recruiting | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    paclitaxel • tovecimig (CTX-009)
    5d
    Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=124, Recruiting, Air Force Military Medical University, China
    New P2 trial • Real-world evidence
    |
    cisplatin • gemcitabine • AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    5d
    Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=35, Recruiting, Shanghai Zhongshan Hospital
    New P2 trial • IO biomarker
    |
    cisplatin • gemcitabine • Epidaza (chidamide)
    8d
    A case of gallbladder adenoma causing gallbladder haemorrhage. (PubMed, J Surg Case Rep)
    Pathological examination of the resected specimen revealed that a pyloric gland adenoma, which was positive for MUC6 and MUC5AC, had detached from its mucosal stalk, leading to significant hemorrhage. Although the primary indication for resecting large gallbladder polyps (≥10 mm) is malignancy risk, this case suggests that the risk of acute haemorrhagic complications from tumour detachment should also be recognized as a strong rationale for surgical intervention.
    Journal
    |
    MUC5AC (Mucin 5AC) • MUC6 (Mucin 6)
    10d
    Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Initiation date: Sep 2025 --> Dec 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • nilvanstomig (ZG005)
    11d
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=168, Completed, Compass Therapeutics | Active, not recruiting --> Completed | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion • Trial primary completion date
    |
    paclitaxel • tovecimig (CTX-009)
    11d
    HERIZON-BTC-302: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P3, N=286, Recruiting, Jazz Pharmaceuticals | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • gemcitabine • Ziihera (zanidatamab-hrii)
    12d
    A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=1100, Recruiting, AstraZeneca | N=232 --> 1100
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    12d
    DiscovHER PAN-206: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors (clinicaltrials.gov)
    P2, N=125, Recruiting, Jazz Pharmaceuticals | N=50 --> 125
    Enrollment change
    |
    HER-2 overexpression
    |
    Ziihera (zanidatamab-hrii)
    12d
    Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, University of Southern California | Trial completion date: Apr 2026 --> Dec 2026
    Trial completion date
    |
    cisplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • sEphB4-HSA